Glaukos Corporation $GKOS Stock Position Decreased by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership lowered its stake in Glaukos Corporation (NYSE:GKOS) by 5.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 287,221 shares of the medical instruments supplier’s stock after selling 15,172 shares during the period. Artisan Partners Limited Partnership owned approximately 0.50% of Glaukos worth $29,667,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of GKOS. Park Place Capital Corp boosted its stake in Glaukos by 68.4% during the second quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares in the last quarter. AlphaQuest LLC lifted its position in Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after purchasing an additional 633 shares during the period. Parkside Financial Bank & Trust grew its holdings in Glaukos by 909.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,252 shares of the medical instruments supplier’s stock worth $129,000 after acquiring an additional 1,128 shares during the period. Bayforest Capital Ltd acquired a new position in shares of Glaukos during the 1st quarter worth about $141,000. Finally, Revisor Wealth Management LLC bought a new stake in Glaukos in the second quarter valued at approximately $204,000. 99.04% of the stock is owned by institutional investors.

Insider Transactions at Glaukos

In other news, COO Joseph E. Gilliam sold 19,340 shares of the stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the transaction, the chief operating officer directly owned 92,366 shares in the company, valued at approximately $8,312,940. This represents a 17.31% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on GKOS shares. The Goldman Sachs Group started coverage on Glaukos in a research report on Wednesday, October 1st. They set a “buy” rating and a $103.00 price objective for the company. Truist Financial set a $120.00 target price on Glaukos in a report on Thursday, October 30th. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. Wells Fargo & Company upped their price target on shares of Glaukos from $120.00 to $122.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. Finally, JPMorgan Chase & Co. upped their target price on Glaukos from $110.00 to $120.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $119.08.

Glaukos Stock Up 4.4%

Shares of NYSE:GKOS opened at $99.36 on Friday. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $163.71. The business has a fifty day moving average price of $84.72 and a two-hundred day moving average price of $91.41. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.51 and a quick ratio of 4.69. The company has a market capitalization of $5.71 billion, a PE ratio of -64.52 and a beta of 0.81.

Glaukos (NYSE:GKOS) last announced its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The business had revenue of $133.54 million for the quarter, compared to analysts’ expectations of $122.55 million. During the same period in the previous year, the business posted ($0.28) EPS. The firm’s quarterly revenue was up 38.1% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Analysts forecast that Glaukos Corporation will post -1.08 earnings per share for the current year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.